Stem Cell Therapy Sophie
This is a before video of Sophie. You can see she is trembling due to t he pain in her hips.

By: Tim O #39;Neill, DVM

Read the original:
Stem Cell Therapy Sophie - Video

By Jocelyn R. Uy Philippine Daily Inquirer

This stem cell therapy could be hazardous to your health.

The Philippine Medical Association (PMA) on Sunday warned Filipinos against availing themselves of the so-called xenogenic stem cell therapy from foreign doctors who fly into the country and perform the procedure in five-star hotels in Metro Manila.

The doctors organization also announced that it had already tapped the help of the National Bureau of Investigation and the Philippine National Police to look into the scam, which it said tainted the legitimate practice of stem cell or regenerative medicine in the country.

Dr. Leo Olarte, PMA president and spokesperson of the Philippine Society for Stem Cell Medicine (PSSCM), disclosed that the two medical groups had received complaints from patients and their relatives who had undergone such stem cell procedures allegedly performed in the country by German doctors.

Based on the complaints, Olarte said the patients were asked to check in at a five-star hotel in the capital, where they were injected with animal-based stem cells at around P1 million per shot.

These foreigners are not even licensed to practice medicine in the country and are in violation of the Medical Act of 1959, Olarte stressed. We are then asking government regulators and enforcers, especially the NBI and the PNP, to investigate these criminal acts.

He warned Filipino doctors to stop collaborating with unscrupulous foreign counterparts or the organization would file criminal cases against them.

If you will continue doing this, we will file criminal cases against you, said Olarte, an orthopedic surgeon and practicing lawyer.

The doctor also stressed that the autologous adult stem cell treatmentderived from the patients own blood, bone marrow or fatwas the only approved stem cell therapy by the Department of Health (DOH) because it had already been proven as the safest procedure available worldwide.

Read the original:
Stem cell therapy in 5-star hotels? Group sees scam

Manila (Philippine Daily Inquirer/ANN) - This stem cell therapy could be hazardous to your health.

The Philippine Medical Association (PMA) on Sunday warned Filipinos against availing themselves of the so-called "xenogenic" stem cell therapy from foreign doctors who fly into the country and perform the procedure in five-star hotels in Metro Manila.

The doctors' organisation also announced that it had already tapped the help of the National Bureau of Investigation and the Philippine National Police to look into the scam, which it said tainted the legitimate practice of stem cell or regenerative medicine in the country.

Dr. Leo Olarte, PMA president and spokesperson of the Philippine Society for Stem Cell Medicine (PSSCM), disclosed that the two medical groups had received complaints from patients and their relatives who had undergone such stem cell procedures allegedly performed in the country by German doctors.

Based on the complaints, Olarte said the patients were asked to check in at a five-star hotel in the capital, where they were injected with animal-based stem cells at around 1 million pesos (US$22,800) per shot.

"These foreigners are not even licensed to practice medicine in the country and are in violation of the Medical Act of 1959," Olarte stressed. "We are then asking government regulators and enforcers, especially the NBI and the PNP, to investigate these criminal acts."

He warned Filipino doctors to stop collaborating with unscrupulous foreign counterparts or the organisation would file criminal cases against them.

"If you will continue doing this, we will file criminal cases against you," said Olarte, an orthopedic surgeon and practising lawyer.

The doctor also stressed that the autologous adult stem cell treatmentderived from the patient's own blood, bone marrow or fatwas the only approved stem cell therapy by the Department of Health (DOH) because it had already been proven as the safest procedure available worldwide.

He discouraged Filipinos from considering xenogenic stem cell sources or those derived from animals and plants, as well as allogeneic sources or from other human beings, due to the many instances of deadly complications from these procedures.

The rest is here:
Stem cell therapy in Philippines' 5-star hotels a scam, says group

Mickey #39;s Before After Stemlogix Stem Cell Therapy
Mickey, a 13 year old German Shepherd torn both of his ACLs and suffered from severe arthritis. Mickey has been treated with Stemlogix Stem Cell Therapy Platelet Max Platelet Rich Plasma...

By: Stemlogix, LLC

View post:
Mickey's Before

Importance of stem cell therapy

By: StemCellVN

Originally posted here:
Importance of stem cell therapy - Video

Two approaches to stem cell therapy for osteoarthritis
http://www.stemcellsarthritistreatment.com There are two potential approaches of stem cell-based cartilage repair and regeneration. The first is ex vivo cart...

By: Nathan Wei

Read more from the original source:
Two approaches to stem cell therapy for osteoarthritis - Video

Stem Cell Therapy at Pondicherry East Coast Hospitals

By: Anupama Karthikeyane

Read more:
Stem Cell Therapy at Pondicherry East Coast Hospitals - Video

WALTHAM, Mass.--(BUSINESS WIRE)--

ViaCord, PerkinElmers family cord blood and tissue preservation business, is collaborating with the Center for International Blood and Marrow Transplant Research (CIBMTR) to collect, maintain and publish research from ViaCords cord blood stem cell transplants. This collaboration will expand knowledge of cord blood-derived stem cell applications throughout the medical and research community. To date, CIBMTRs large network of transplant centers has resulted in the development of a clinical database of more than 30,000 cord blood transplant recipients for clinical decision-making, use in studies, and other research purposes with the goal of making a profound impact on the survival of cord blood transplant patients around the world. CIBMTR will work directly with ViaCord to collect and analyze data to better understand the quality and any outcome metrics of ViaCords released cord blood stem cell units as well as how the units are being used.

Collaborating with CIBMTR, which has established the industry standard for collecting data around hematopoietic cellular therapy and regenerative medicine, allows us to simultaneously gain insights into the effectiveness of the cord blood stem cell units we have released for use as well as outcomes from their clinical application, said Morey Kraus, Chief Scientific Officer, ViaCord. We are then able to incorporate data from our transplanted units into the larger database, which may be accessed for other CIBMTR studies by the medical and scientific community to further their research and understanding of cord blood stem cells.

ViaCord is working with CIBMTR to collect and publish data as well as identify outcomes unique to related or autologous (stem cells from the same patient) transplants. The collaboration will also enable the analysis of umbilical cord units released for potential future use in autologous cell therapy and regenerative medicine clinical trials, including Cerebral Palsy, Type 1 Diabetes and others.

The science of cord blood and cord tissue stem cells is growing at a rapid pace, said J. Douglas Rizzo, M.D., M.S., Associate Scientific Director, CIBMTR. We are excited to collaborate with ViaCord to provide data and analytic expertise that will assist the development of the field through research.

ViaCord's family cord blood banking services currently offers expectant families the opportunity to preserve their baby's umbilical cord blood for potential medical use by the child or a related family member. Families are also preserving their babys umbilical cord tissue because research suggests that one day these special cells may have the potential to treat medical conditions that are untreatable today. ViaCord has preserved the umbilical cord blood of more than 300,000 newborns. Twenty years ago, cord blood stem cells were used to treat just one disease, Fanconi's anemia. Today, cord blood stem cells have been used in the treatment of nearly 80 diseases, including cancers, certain blood disorders and immunodeficiencies. Please visit http://www.viacord.com for more information.

Factors Affecting Future Performance This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in the supply of raw materials and supplies; (11) the manufacture and sale of products exposing us to product liability claims; (12) our failure to maintain compliance with applicable government regulations; (13) regulatory changes; (14) our failure to comply with healthcare industry regulations; (15) economic, political and other risks associated with foreign operations; (16) our ability to retain key personnel; (17) significant disruption in our information technology systems; (18) our ability to obtain future financing; (19) restrictions in our credit agreements; (20) our ability to realize the full value of our intangible assets; (21) significant fluctuations in our stock price; (22) reduction or elimination of dividends on our common stock; and (23) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About the Center for International Blood and Marrow Transplant Research(CIBMTR) A combined research program of the National Marrow Donor Program and the Medical College of Wisconsin, the CIBMTR facilitates critical, cutting-edge research that has led to increased survival and an enriched quality of life for thousands of patients. The CIBMTR collaborates with the global scientific community to advance hematopoietic cell transplantation and cellular therapy research worldwide. The prospective and observational research is accomplished through scientific and statistical expertise, a large network of transplant centers and clinical database of more than 350,000 transplant recipients.

About PerkinElmer, Inc. PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The company reported revenue of approximately $2.1 billion in 2012, has about 7,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at http://www.perkinelmer.com.

View original post here:
ViaCord® to Advance Cord Blood Stem Cell Therapy Research through Collaboration with the Center for International ...

Stem Cell Patient Treated With Adult Stem Cell Therapy

By: Shaun Scott

More:
Stem Cell Patient Treated With Adult Stem Cell Therapy - Video

ALLENDALE, N.J., April 29, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) and its subsidiary, Progenitor Cell Therapy LLC ("PCT"), announced today the execution of a Services Agreement with Sentien Biotechnologies, Inc. ("Sentien") under which PCT will provide services to support Sentien's development of its cell therapy product, including technology transfer, staff training, and manufacturing.

Sentien is developing an allogeneic cell therapy product consisting of bone marrow derived mesenchymal stem cells seeded onto a medical device for critical care indications. Sentien has engaged PCT for manufacture of the final formulation of its cell therapy product and intends to transfer and implement Sentien's master cell bank, product working cell bank and product manufacturing processes to PCT. These cell banks will be prepared according to Good Manufacturing Practices ("GMP") guidelines and implemented by PCT to create a cell therapy product for Sentien's Investigational New Drug ("IND") submission to the FDA. Upon obtaining an IND, Sentien intends to have PCT manufacture GMP compliant grade materials to support Sentien's Phase I clinical trial.

"We are excited to enter into this agreement with Sentien, an innovator for acute organ failure," said Robert A. Preti, PhD, President and Chief Scientific Officer of PCT. PCT is an internationally recognized contract development and manufacturing organization with facilities in Allendale, New Jersey and Mountain View, California. The company has expertise in GMP manufacture for cell therapies, including dendritic cells, stem cells and T cells. Notably, PCT provided manufacturing for the pivotal studies for Dendreon's Provenge(R), the first cell therapy approved for cancer treatment.

About NeoStem, Inc.

NeoStem, Inc. ("NeoStem" or the "Company") is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization ("CDMO") providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation. http://www.neostem.com

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's research and development and clinical evaluation efforts for cellular therapies, including with respect to AMR-001, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the Company's ability to successfully grow its contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2013 and in the Company's periodic filings with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

Here is the original post:
NeoStem's Subsidiary, Progenitor Cell Therapy, Enters Into a Services Agreement With Sentien Biotechnologies, Inc.

LA JOLLA, Calif., April 22, 2013 /PRNewswire-USNewswire/ -- In a serendipitous discovery, scientists at The Scripps Research Institute (TSRI) have found a way to turn bone marrow stem cells directly into brain cells.

Current techniques for turning patients' marrow cells into cells of some other desired type are relatively cumbersome, risky and effectively confined to the lab dish. The new finding points to the possibility of simpler and safer techniques. Cell therapies derived from patients' own cells are widely expected to be useful in treating spinal cord injuries, strokes and other conditions throughout the body, with little or no risk of immune rejection.

"These results highlight the potential of antibodies as versatile manipulators of cellular functions," said Richard A. Lerner , the Lita Annenberg Hazen Professor of Immunochemistry and institute professor in the Department of Cell and Molecular Biology at TSRI, and principal investigator for the new study. "This is a far cry from the way antibodies used to be thought ofas molecules that were selected simply for binding and not function."

The researchers discovered the method, reported in the online Early Edition of the Proceedings of the National Academy of Sciences the week of April 22, 2013, while looking for lab-grown antibodies that can activate a growth-stimulating receptor on marrow cells. One antibody turned out to activate the receptor in a way that induces marrow stem cellswhich normally develop into white blood cellsto become neural progenitor cells, a type of almost-mature brain cell.

Nature's Toolkit

Natural antibodies are large, Y-shaped proteins produced by immune cells. Collectively, they are diverse enough to recognize about 100 billion distinct shapes on viruses, bacteria and other targets. Since the 1980s, molecular biologists have known how to produce antibodies in cell cultures in the laboratory. That has allowed them to start using this vast, target-gripping toolkit to make scientific probes, as well as diagnostics and therapies for cancer, arthritis, transplant rejection, viral infections and other diseases.

In the late 1980s, Lerner and his TSRI colleagues helped invent the first techniques for generating large "libraries" of distinct antibodies and swiftly determining which of these could bind to a desired target. The anti-inflammatory antibody Humira, now one of the world's top-selling drugs, was discovered with the benefit of this technology.

Last year, in a study spearheaded by TSRI Research Associate Hongkai Zhang, Lerner's laboratory devised a new antibody-discovery techniquein which antibodies are produced in mammalian cells along with receptors or other target molecules of interest. The technique enables researchers to determine rapidly not just which antibodies in a library bind to a given receptor, for example, but also which ones activate the receptor and thereby alter cell function.

Lab Dish in a Cell

For the new study, Lerner laboratory Research Associate Jia Xie and colleagues modified the new technique so that antibody proteins produced in a given cell are physically anchored to the cell's outer membrane, near its target receptors. "Confining an antibody's activity to the cell in which it is produced effectively allows us to use larger antibody libraries and to screen these antibodies more quickly for a specific activity," said Xie. With the improved technique, scientists can sift through a library of tens of millions of antibodies in a few days.

Go here to read the rest:
Scripps Research Institute Scientists Find Antibody that Transforms Bone Marrow Stem Cells Directly into Brain Cells

Stem Cell Therapy - Blue Horizon Stem Cells

By: Michael McDermott

The rest is here:
Stem Cell Therapy - Blue Horizon Stem Cells - Video

Performance After Adipose Stem Cell Therapy for Horse - Cash Fuez and Flaxey
Performance After Adipose Stem Cell Therapy for Horse - Cash Fuez and Flaxey http://wichitaequinevet.com "This is the video of Flaxey after he and Cash won t...

By: WichitaEquine

Read more:
Performance After Adipose Stem Cell Therapy for Horse - Cash Fuez and Flaxey - Video

Stem Cell Therapy Treatment for Duchenne Muscular Dystrophy by Dr Alok Sharma, Mumbai, India.
Stem Cell Therapy Treatment for Duchenne Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy PT assessment: 1) In walking, whole foo...

By: neurogenbsi

Originally posted here:
Stem Cell Therapy Treatment for Duchenne Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. - Video

Stem Cell Therapy Treatment for Spinal Cord Injury by Dr Alok Sharma, Mumbai, India.
Stem Cell Therapy Treatment for Spinal Cord Injury by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. Ankle clonus/jerk in both legs has reduced. P...

By: neurogenbsi

Link:
Stem Cell Therapy Treatment for Spinal Cord Injury by Dr Alok Sharma, Mumbai, India. - Video

LONDON (SHARECAST) - ReNeuron Group has won two grants worth 1.2m pounds to develop its stem cell therapy.

The grants were awarded by the UK Biomedical Catalyst, a programme of public funding jointly managed by the Technology Strategy Board and the Medical Research Council.

The first award of 0.4m will be used for ReNeurons ReN009 stem cell therapy candidate for critical limb ischaemia, a severe blockage in the arteries which markedly reduces blood-flow to the extremities including hands, feet and legs.

The second award of 0.8m relates to the company's ReN003 stem cell candidate for the treatment of retinitis pigmentosa, an eye disease in which there is damage to the retina.

Michael Hunt, the Chief Executive Officer of ReNeuron, said: "We are delighted to have been successful in winning the two grants we applied for in the current round of the Biomedical Catalyst funding competition.

"This highly competitive scheme involves a rigorous peer review of applicants' technologies and commercial development plans.

"In common with other awardees, we therefore regard the grants as representing a strong independent endorsement of ReNeuron's world-class stem cell development capabilities which we hope will eventually lead to the wide-scale treatment of disease conditions where there is currently a very large unmet medical need."

Shares rose 0.86% to 2.94p at 08:52 Monday.

RD

See the original post here:
ReNeuron Group wins grants for stem cell therapy development

Stem Cell Therapy for Autism Part 1
He is a known case of Autism with history of full term caesarean section delivery and cried immediately after birth with near normal motor milestones. But as he was put in school, there were regular complaints of him being hyperactive. He was then diagnosed to have Autism. He was shifted to special school then. Neurologically, he has near normal tone, reflexes and muscle power. On examination: he has hyperactivity. He has aggressive behaviour with episodes of violence and beating others. He has repetitive speech (echolalia), but it is need based. He has social isolation. He is bowel bladder trained. He is independent in most ADL. Functionally, he needs supervision in most ADL. On FIM he scores 106. After Stem Cell Therapy 1. Angry spells are short lasting than before. Earlier, if he used to be upset for half hour at a stretch, now he calms down in 2 minutes. 2. Did not ask for toothpaste for second time which he used to do daily. 3. He does not insist on bathing 2-3 times a day like before. Now, he takes bath once a day. 4. Visits washroom once in 2-3 hours and then washes his hand normally and leaves the washroom. Earlier, he used to go to washroom every hourly and wash his hand, spill water on his clothes and arms. 5. Eye contact attention span improved. 6. Sitting tolerance improved and attends for 30 mins session. 7. Listening skills and observation skills on demand improved. 8. Screaming behavior reduces when given paper tearing activity. 9. His parents feel his ...

By: neurogenbsi

More:
Stem Cell Therapy for Autism Part 1 - Video

Baylie Faella Pre-Stem Cell Therapy at Abbott Animal Hospital in Rehoboth, MA
Baylie Faella, a 7 year old Lab pre-stem cell therapy who underwent a torn ACL repair. She also suffered from atopy (allergies) and had lesions on her body.

By: Ashraf Gomaa

See the rest here:
Baylie Faella Pre-Stem Cell Therapy at Abbott Animal Hospital in Rehoboth, MA - Video

Public release date: 21-Feb-2013 [ | E-mail | Share ]

Contact: Sooike Stoops sooike.stoops@vib.be 32-924-46611 VIB (the Flanders Institute for Biotechnology)

Cell therapy is a promising alternative to tissue and organ transplantation for diseases that are caused by death or poor functioning of cells. Considering the ethical discussions surrounding human embryonic stem cells, a lot is expected of the so-called 'induced pluripotent stem cells' (iPS cells). However, before this technique can be applied effectively, a lot of research is required into the safety and efficacy of such iPS cells. VIB scientists associated to the UGent have developed a mouse model that can advance this research to the next step.

Lieven Haenebalcke (VIB/UGent): "iPS cells have enormous therapeutic potential, but require more thorough testing before they can be used for such purposes. Using our new mouse model, we can study which mechanisms determine the identity of a cell. This knowledge is essential before we can use cell therapy for regenerative medicine."

Jody Haigh (VIB/UGent): "If we want to give cell therapy a future, then we must continue this type of research and invest in the further development of such technologies. This will result in an improved insight into cellular identity and in the long term safer options of applying iPS cells or cells derived from iPS cells in clinical studies."

Cell therapy replacing cells to provide a cure

Cell therapy is the replacement of lost or poorly functioning cells in patients. For example, such cell therapies could be used to repair the heart muscle after a heart attack, joints affected by arthritis, the pancreas in diabetes or the spine in certain forms of paralysis. This requires cells that are able to multiply in the laboratory and that can be converted to healthy cells of the desired cell type. Human embryonic stem cells meet these criteria, but they are ethically controversial.

iPS cells a promising alternative to embryonic stem cells

Shinya Yamanaka recently developed a fairly simple method to reprogram differentiated cells such as skin cells back to stem cells, so-called "induced pluripotent stem cells" (iPS cells). This earned him the Nobel Prize for Medicine in 2012 (shared with John Gurdon). These iPS cells can be generated using only 4 "reprogramming factors".

As is the case with embryonic stem cells, these iPS cells can be used to produce other cell types, such as heart muscle cells or nerve cells. They can also be cultured indefinitely and there are no ethical objections as they are not obtained from human embryos left over after IVF, but from adult individuals. Furthermore, iPS cells are obtained from the patient and this reduces the risk of rejection during therapeutic applications.

Read the rest here:
Cell therapy a little more concrete thanks to VIB research

Beckers Muscular Dystrophy After Stem Cell Therapy in Mumbai India
He is a 12 year old and a known case of BMD with history of gradual onset of progressive lower extremities muscle weakness since age of 7 years with complaints of difficulty in climbing stairs, getting up from floor. Weakness even progressed to upper extremities with difficulty in overhead activities and frequent falls. No family history. On examination, he has grade 3 #713; muscle power in proximal muscles of both upper extremities and lower extremities and 4 in distal muscles of both upper extremities and lower extremities. He has bilateral pseudohypertrophy of calf muscles and walks on toes. Neurologically, he is hypotonic and hyporeflexic. Functionally, he is independent in most of the ADL, needs assistance in lower body dressing. On FIM he score 109. After Stem Cell Treatment 1. Reports overall feeling of freshness and energetic. 2. Can manage to walk on heels. Earlier he would walk on toes. 3. Posture has improved. Earlier he would walk with lordosis. 4. Earlier he would need maximum support for stair climbing from both railing and one hand on knee, now only uses railing to climb stairs. 5. Stamina has improved and he has increased level of confidence. 6. Sit to stand and stand to sit transfers requires less efforts. 7. Can perform overhead activities with ease and maintains for a longer time. 8. Is more active than before. 9. Speech is clear and loud followed by deep inhalation and slow rate with prolongation technique. 10. Secondary behaviors also reduced like reduced ...

By: neurogenbsi

See the article here:
Beckers Muscular Dystrophy After Stem Cell Therapy in Mumbai India - Video